ArriVent BioPharma, Inc. (AVBP) earnings date
Mar 4, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | after close | 43 | 8-K |
| Q1 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | after close | 64 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | before open | 42 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | before open | 42 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | before open | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "· Cash and investments of $393.2 million as of September 30, 2026 expected to fund operations to mid-2028" exhibit |
| Q3 FY2026 | "Phase 1b dose optimization data for ARR-217 in late line colorectal cancer are expected in the first half of 2027, and ARR-217 combination data with bevacizumab as well as combination data with chemotherapy are expected in the second half of 2027." exhibit |
| Q3 FY2026 | "· As of September 30, 2026, the Company had cash and investments of $393.2 million, which is expected to fund operations to mid-2028." exhibit |
| Q2 FY2026 | "· Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026" exhibit |
| Q2 FY2026 | "· Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026" exhibit |
| Q2 FY2026 | "· Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028" exhibit |
| Q2 FY2026 | "Dosing of first patient with ARR-002 in a Phase 1 trial expected in the third quarter of 2026." exhibit |
| Q2 FY2026 | "· As of June 30, 2026, the Company had cash and investments of $373.1 million, which is expected to fund operations into 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AVBP
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AVBP
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AVBP/"><img src="https://veritasdata.dev/embed/AVBP.svg" alt="AVBP earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AVBP/)
Script
<script async src="https://veritasdata.dev/embed/AVBP.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AVBP"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.